Navigation Links
Neurocrine Biosciences Reports Second Quarter 2014 Results
Date:8/6/2014

2459 (US) or 402-220-7218 (International) using the conference ID: NBIX.  The call will be archived for one month.

Neurocrine Biosciences, Inc. discovers and develops innovative and life-changing pharmaceuticals, in diseases with high unmet medical needs, through its novel R&D platform, focused on neurological and endocrine based diseases and disorders.  The Company's two lead late-stage clinical programs are elagolix, a gonadotropin-releasing hormone antagonist for women's health that is partnered with AbbVie Inc., and a wholly owned vesicular monoamine transporter 2 inhibitor for the treatment of movement disorders.  Neurocrine intends to maintain certain commercial rights to its VMAT2 inhibitor for evolution into a fully-integrated pharmaceutical company.

Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at http://www.neurocrine.com.

In addition to historical facts, this press release may contain forward-looking statements that involve a number of risks and uncertainties.  Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with Neurocrine's R&D pipeline as well as its business overall.  Specifically, the risks and uncertainties the Company faces with respect to its lead program, elagolix, include the risk that the elagolix endometriosis Phase III clinical trials will fail to demonstrate that elagolix is safe and effective; the risk that elagolix Phase III clinical trials will be delayed for regulatory or other reasons; the risk that the elagolix uterine fibroids clinical program will not proceed to later stage clinical trials; and the risks associated with the Company's dependence on AbbVie for elagolix Phase III development, commercial manufacturing and marketing and sales activities.  In additi
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results
2. Neurocrine Biosciences Reports First Quarter 2012 Results
3. Neurocrine Biosciences to Present at the Jefferies 2012 Global Healthcare Conference
4. Neurocrine Biosciences Announces Conference Call And Webcast To Present Second Quarter 2012 Financial Results
5. Neurocrine Biosciences To Present At The Morgan Stanley Global Healthcare Conference
6. Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2012 Financial Results
7. Neurocrine Biosciences To Present At Lazard Capitalmarkets 9th Annual Healthcare Conference
8. Neurocrine Biosciences To Present At Deutsche Banks 2012 dbAccess BioFEST
9. Neurocrine Biosciences Announces Additional European And United States Patents Issued On Proprietary VMAT2 Inhibitor
10. Neurocrine Biosciences Announces Conference Call And Webcast To Present Fourth Quarter And Year-End 2012 Financial Results
11. Neurocrine Biosciences To Present At The Leerink Swann Global Healthcare Conference 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... and MENLO PARK, Calif. ... DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) (DelMar and ... commercializing proven cancer therapies in new orphan drug ... of Allowance from the U.S. Patent and Trademark ... " Compositions and methods to improve the therapeutic ...
(Date:3/2/2015)... , March 2, 2015 Attorney ... investigating potential claims on behalf of purchasers of ... or the "Company") (NasdaqGM: VTAE -News).  Such investors ... or his investor relations coordinator Eitan Kimelman ... The investigation concerns whether Vitae Pharmaceuticals and ...
(Date:3/2/2015)... Calif. , March 2, 2015 Valencia ... 48 th patient with its radically small device ... 10, 2015. Valencia,s early results in this randomized, double-blinded, controlled ... high degree of confidence that it will succeed in ... With its early clinical results, Valencia ...
Breaking Medicine Technology:DelMar Pharmaceuticals Receives Notice of Allowance of Fourth U.S. Patent Covering Methods of Use and Compositions for VAL-083 2DelMar Pharmaceuticals Receives Notice of Allowance of Fourth U.S. Patent Covering Methods of Use and Compositions for VAL-083 3DelMar Pharmaceuticals Receives Notice of Allowance of Fourth U.S. Patent Covering Methods of Use and Compositions for VAL-083 4SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Vitae Pharmaceuticals, Inc. 2Valencia Technologies Implants its 48th Patient, Continues Equity Crowdfunding 2
... April 23, 2007 /PRNewswire-FirstCall/,Micromet, Inc. today announced ... collaboration with MedImmune, Inc. for the development,of ... validated tumor- associated antigen frequently expressed on,various ... 2007 Annual Meeting of the American Association ...
... 23, 2007 - Aeolus,Pharmaceuticals, Inc. (OTCBB:AOLS) announced ... Linda University Medical Center showing,that one of ... an important role regulating the oxidative damage,induced ... alone or in combination with surgery,and chemotherapy ...
Cached Medicine Technology:Micromet Achieves Milestone in BiTE Research Collaboration with,MedImmune 2Micromet Achieves Milestone in BiTE Research Collaboration with,MedImmune 3Micromet Achieves Milestone in BiTE Research Collaboration with,MedImmune 4Aeolus Pharmaceuticals' AEOL 10113 May Play an Important Role,Regulating the Oxidative Damage Induced by Ionizing Radiation 2Aeolus Pharmaceuticals' AEOL 10113 May Play an Important Role,Regulating the Oxidative Damage Induced by Ionizing Radiation 3
(Date:3/2/2015)... March 02, 2015 GBCHealth, a ... catalyzing private sector activities and investments in global ... elected four new members to serve on the ... Paul Farmer, Chief Strategist and Co-founder of Partners ... University; Dr. Huma Abbasi, General Manager of Global ...
(Date:3/2/2015)... March 02, 2015 Market Publishers Ltd ... worked out by Global Industry Analysts Inc and recently ... Market Research Report . Through 2018, the global radiation ... CAGR. The detailed research report suggests a holistic analysis ... therapy equipment as well as covers the top market ...
(Date:3/2/2015)... Just months after the U.S. ... use of power morcellators ( http://www.morcellatorlawsuit2015.com ) in ... UnitedHealthCare is poised to restrict coverage for hysterectomies ... a notification sent to physicians in January, the ... require pre-authorization for laparoscopic or abdominal hysterectomies, the ...
(Date:3/2/2015)... March 02, 2015 While many hospitals ... VI of the Civil Rights Act, the unique needs ... loss are bringing light to the value of video ... that nearly 1 in 20 U.S. children have LEP—a ... in some major cities.(1) Stratus Video Interpreting ...
(Date:3/2/2015)... 2015 Doctors in Novara, Italy have ... predictor of outcomes for people with mesothelioma than other ... of the new study on the Surviving Mesothelioma website. ... of Eastern Piedmont followed the cases of 172 ... excess lung fluid. , “Persistent lung expansion after ...
Breaking Medicine News(10 mins):Health News:Dr. Paul Farmer and Leaders from Chevron, Johnson & Johnson and Merck Join GBCHealth’s Board of Directors 2Health News:Dr. Paul Farmer and Leaders from Chevron, Johnson & Johnson and Merck Join GBCHealth’s Board of Directors 3Health News:Dr. Paul Farmer and Leaders from Chevron, Johnson & Johnson and Merck Join GBCHealth’s Board of Directors 4Health News:Dr. Paul Farmer and Leaders from Chevron, Johnson & Johnson and Merck Join GBCHealth’s Board of Directors 5Health News:New Topical Research Reports Prepared by GIA Now Available at MarketPublishers.com 2Health News:New Topical Research Reports Prepared by GIA Now Available at MarketPublishers.com 3Health News:Power Morcellator Lawyers at Bernstein Liebhard LLP Comment on Insurers’ Decision to Restrict Most Common Form of Hysterectomies 2Health News:Power Morcellator Lawyers at Bernstein Liebhard LLP Comment on Insurers’ Decision to Restrict Most Common Form of Hysterectomies 3Health News:Power Morcellator Lawyers at Bernstein Liebhard LLP Comment on Insurers’ Decision to Restrict Most Common Form of Hysterectomies 4Health News:Stratus Video Addresses Inadequate Language Interpreting for 2.4 Million U.S. Children 2Health News:Stratus Video Addresses Inadequate Language Interpreting for 2.4 Million U.S. Children 3Health News:Stratus Video Addresses Inadequate Language Interpreting for 2.4 Million U.S. Children 4Health News:New Research Links Talc Treatment Response with Mesothelioma Prognosis, According to Surviving Mesothelioma 2
... recent Florida State University study, hospitals can combat spiralling ... all hospital operations. ,According to Ken Lubben, ... and Lakewood Ranch Medical Centre, have already made big ... He said that, the hospitals are yet to reap ...
... official of China the tide has ebbed and has declared ... in the province.// ,But as a damper this claim ... senior health official was Luo Huiming, director of the Guangdong ... Institute. ,He said, "The weather has begun to get ...
... the Emirates are concerned with the proposal of the Ministry ... in the country.// ,"A committee has been set ... ministry provides for the private medical sector. This includes the ... staff, and the licensing of the medical or health establishments ...
... with avian influenza infection was Saturday admitted to ... a 30-year-old resident of Jamalpur neighborhood of the ... ,Gujarat's Health Minister Ashok Bhatt, however, denied ... negative results., ,According to Bhatt, the blood ...
... has finally broken a taboo with a study on the ... General Union of Women// supported with funds from the United ... four married women gets beaten -- usually by her husband ... awareness of the problem. ,In Syria violence against ...
... times as much sunlight as those with fair skin to ... study// . ,Researchers at the Australian National University ... summer sunshine to produce enough Vitamin D whereas dark-skinned people ... ,Acceptable levels of sunbathing also depends on geography and the ...
Cached Medicine News:Health News:Technology Can Help Fight Health Care Costs 2Health News:Technology Can Help Fight Health Care Costs 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: